Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 925.85% | 109.01% | -69.14% | -212.10% | 185.24% |
| Total Depreciation and Amortization | -2.42% | 13.27% | 0.81% | 1.44% | -5.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -178.66% | 2.68% | 3.99% | 7.30% | 10.07% |
| Change in Net Operating Assets | -268.76% | -59.80% | 338.93% | 148.11% | 27.14% |
| Cash from Operations | -84.90% | 113.10% | 56.79% | -58.40% | 324.39% |
| Capital Expenditure | 11.57% | 3.99% | -85.71% | 62.20% | -12.78% |
| Sale of Property, Plant, and Equipment | 809.52% | -72.37% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -23,500.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -320.13% | -594.13% | 157.82% | -116.84% | -30.71% |
| Cash from Investing | -301.25% | -881.85% | 135.14% | -119.80% | -32.60% |
| Total Debt Issued | 55,600.00% | 266.67% | -100.22% | -- | -- |
| Total Debt Repaid | 0.71% | -0.72% | 0.00% | 0.71% | -1.45% |
| Issuance of Common Stock | 468.03% | -88.06% | 143.28% | -58.86% | 178.91% |
| Repurchase of Common Stock | 41.13% | -332.00% | -1,791.89% | 99.58% | -306.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69.88% | -606.25% | -206.08% | 104.78% | -307.95% |
| Foreign Exchange rate Adjustments | 260.98% | -141.69% | 33.45% | 305.95% | -155.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -307.03% | -277.91% | 480.87% | -62.23% | -87.53% |